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The aim of this study is to investigate the risk of developing prognostic different types of breast cancer in women using hormone
replacement therapy (HRT). A total of 10874 postmenopausal Danish Nurses were followed since 1993. Incident breast cancer
cases and histopathological information were retrieved through the National Danish registries. The follow-up ended on 31
December 1999. Breast cancer developed in 244 women, of whom 172 were invasive ductal carcinomas. Compared to never users,
current users of HRT had an increased risk of a hormone receptor-positive breast cancer, but a neutral risk of receptor-negative
breast cancer, relative risk (RR) 3.29 (95% confidence interval (CI): 2.27–4.77) and RR 0.99 (95% CI: 0.42–2.36), respectively (P for
difference¼0.013). The risk of being diagnosed with low histological malignancy grade was higher than high malignancy grade with
RR 4.13 (95% CI: 2.43–7.01) and RR 2.17 (95% CI: 1.42–3.30), respectively (P¼0.063). For breast cancers with other prognostic
characteristics, the risk was increased equally for the favourable and nonfavourable types. Current users of HRT experience a two- to
four-fold increased risk of breast cancer with various prognostic characteristics, both the favourable and nonfavourable types. For
receptor status, the risk with HRT was statistically significantly higher for hormone receptor-positive breast cancer compared to
receptor-negative breast cancer.
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Several studies have proposed that breast cancers diagnosed in
women using hormone replacement therapy (HRT) may be
smaller, with less spread to the regional lymph nodes (LN) and
of lower histological malignancy grade, compared with those of
never users. These findings could partly be explained by the
biological influence of exogenous sex hormones on breast tissue as
well as surveillance of women using HRT. The latest pooled
analysis in 1997 concluded that breast cancers diagnosed in ever
users of HRT were less likely to have spread to the regional lymph
nodes or more distant sites compared to those developing in
women never having used HRT. Furthermore, the excess risk of
breast cancer in current or recent users was confined to localised
disease. A total of 54% of the pooled studies contributed to this
analysis (Collaborative Group on hormonal factors in breast
cancer, 1997). Recent studies have added to the evidence, and
found that use of HRT at the time of diagnosis is associated with
one or more favourable prognostic characteristics, such as smaller
tumour size, less regional lymph node involvement, lower tumour
grade and lower stage of disease (Harding et al, 1996; Magnusson
et al, 1996; Holli et al, 1997; Bilimoria et al, 1999; Ross et al, 2000;
Esteve et al, 2002; Sacchini et al, 2002; Gertig et al, 2003;
Kerlikowske et al, 2003). Other studies have not been able to detect
such associations (Schairer et al, 2000; Stallard et al, 2000). Based
on in vivo studies, it has been suggested that, while the effect of
oestrogens is tumour promoting and carcinogenic, the effect of
progestins on breast epithelium is both proliferative and inhibitory
and that progesterone induces cellular differentiation (Thuneke
et al, 2000; Alkhalaf et al, 2002; Lin et al, 2003). Breast carcinomas
developing in premenopausal women and during or short after
pregnancy, when endogenous levels of both oestrogens and
progestins are high, have been found to be associated with poor
histological and prognostic factors (Middleton et al, 2003; Reed
et al, 2003).
Increased surveillance of women using HRT may contribute to
the findings of apparently more favourable prognostic breast
cancer types at the time of diagnosis and some studies find that
adjusting for mammographic screening diminishes the magnitude
of the effect (Daling et al, 2003). Results from the WHI trial in USA
showed that breast cancers diagnosed in women randomised to
HRT were of the same histology and grade as breast cancers
diagnosed in the placebo group. However, with a difference of
mean 2mm, the tumours in HRT users were significantly larger
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land at a more advanced stage at the time of diagnosis, than
tumours developing in the placebo group. Difficulties in detecting
smaller tumours could be due to the higher percentage of
increased mammographic density found in users of HRT, leading
to delayed diagnosis (Chlebowski et al, 2003). Others have found
that despite a lower probability of detecting early breast cancers in
users of HRT at the time of mammographic examinations, the
histological malignancy grade was lower in HRT users compared
to never users (Esteve et al, 2002).
Only a few studies have analysed the different prognostic
characteristics in breast cancer according to different HRT types
and regimens (Magnusson et al, 1996; Ross et al, 2000; Schairer
et al, 2000; Daling et al, 2003). Traditionally, HRT types and
regimens have differed in the USA and some parts of Europe,
especially in the Scandinavian countries. European studies have in
general tended to report higher risk estimates of breast cancer in
users of HRT, especially following the use of the continuous
combined regimen with oestradiol and testosterone-like progestins.
(Magnusson et al, 1999, 2000; Jernstrom et al, 2003; Olsson et al,
2003; Stahlberg et al, 2004). Recently, the Million Women Study
from the UK found an increased risk of breast cancer, most
pronounced for the combined oestrogen plus progestin treatment,
but with no difference in risk estimates with respect to the cyclical
or continuous treatment mode (Beral, 2003). The issue to be solved
is whether different types and regimens of HRT influence the risk of
developing breast cancer with various prognostic characteristics.
Most studies have analysed the distribution of the various
prognostic factors of breast cancer according to the use of HRT, in
women who have already developed the disease. This will not
answer the question whether the risk of developing a favourable
breast cancer is actually higher or lower than the risk of developing
a non-favourable breast cancer for users of HRT compared to
never users.
The aim of this study was to investigate how the current use of
different HRT types and regimens at baseline influences the risk of
breast cancers of both favourable and nonfavourable prognostic
characteristics at the time of diagnosis, in a population of natural
postmenopausal women without prior cancer diseases; further-
more, to assess if there is any difference between these risk
estimates.
MATERIALS AND METHODS
The setting of the Danish nurse cohort and the definition and
characteristics of the study population has previously been
described in detail (Stahlberg et al, 2004). Briefly, the Danish
nurse cohort was established in 1993, when all Danish nurses
above the age of 44 years received a mailed questionnaire
(Hundrup et al, 2000). A total of 19898 returned the questionnaire
(86%).
Ascertainment of exposure and possible confounders
The mailed questionnaire of 1993 served as baseline information.
The questionnaire comprised detailed questions on the current use
of HRT, including type, regimen and duration of use. Brand names
were listed to facilitate the identification of HRT type. Further-
more, the questionnaire included details on known risk factors for
breast cancer such as menarche, parity, age at first birth, alcohol
use, physical activity, BMI, benign breast disease, oral contra-
ceptives, hysterectomies performed, menopausal status and type of
menopause.
Ascertainment of end point
Breast cancer cases were identified by linkage to the Danish Cancer
Registry (a registry with information on all cancer diagnoses since
1943), the Danish Breast Cancer Group Cooperation (DBCG)
register (a clinical database on all breast cancer operations in
Denmark including information on prognostic factors and
histopathological details at the time of diagnosis since 1977) and
the Lands patient Register (LPR) registry (the National Registry of
Patients containing information on all hospital admissions,
discharge diagnoses and operations performed since 1977). Self-
reported information was evaluated together with the data derived
from the registries. Information on tumour type, histological
malignancy grade, hormone receptor status, axillary lymph status
and stage of disease was obtained from the DBCG register. The
follow-up started with the questionnaire in 1993, and ended on 31
December 1999.
Analysis
The cohort comprised a total of 19898 responders at baseline. We
excluded all previously identified breast cancer cases, carcinoma in
situ (CIS) of the breast and other invasive cancers, except for non-
melanoma skin cancer (n¼1086) at baseline. Furthermore, women
with missing information on HRT (n¼267), premenopausal
women (n¼5084) and women with a surgical menopause
(n¼571) were excluded. Also, hysterectomised women
(n¼2016) were excluded, as information on menopausal status
and age at menopause would be missing in these women, which
could seriously bias the analyses as described by Pike et al (1998).
More than one exclusion criterion was fulfilled for several women.
Finally, a total of 10874 women were available for follow-up and
analysis.
Women were considered postmenopausal if the menstrual
bleeding had ceased or they were currently using HRT. The
variable on menopausal age was constructed using the age at
initiating HRT use or the cessation of menstrual bleeding,
whichever event occurred first. The different HRT brands reported
in the questionnaire were categorised according to the type and
regimens used at baseline, that is, the systemic use of oestrogen
only and oestrogen combined cyclically or continuously with
progestin. Vaginal applied oestrogen users were considered non-
users.
Data on prognostic characteristics were available from the
DBCG Registry. The following variables were created: tumour size:
p2cm/42cm, axillary lymph status: neg/pos, histological malig-
nancy grade: grade 1/grade 2 and 3, oestrogen and progesterone
receptor status: pos/neg, histology: invasive ductal/lobular/others.
Information on staging was computed: stage according to TNM:
stage1/stage 2–4. Nottingham Prognostic Index (NPI) was
calculated as (tumour size (cm) 0.2)þmalignancy grade 1–
3þlymph nodes 1–3 (1¼neg, 2¼1–3 pos LN, 3¼more than 3
pos LN). The index was grouped into good prognosis (scoreo3.4)/
moderate prognosis (score 3.5–5.4)/poor prognosis (score 45.4)
(Haybittle et al, 1982). The analysis on prognostic characteristics
was restricted to invasive ductal carcinomas.
Statistical analysis
The Cox Proportional Hazards (PH) Model for left-truncated and
right-censored data was used in the modelling of time-to-breast-
cancer outcomes. The nurse’s age was used as an underlying time
with the age at study entry as the delayed entry time in the
analysis. Women with histologies other than invasive ductal
carcinomas were censored at the time of breast cancer diagnosis,
as well as breast cancers with missing information on one of the
prognostic characteristics. The various prognostic different breast
cancer types were considered as single end points. Each prognostic
factor was modelled in a multivariate Cox PH model, where
relative risk (RR) and their 95% confidence intervals were
estimated for HRT-exposure variable, adjusted for only significant
risk factors (age at menopause, age at menarche, parity, age at first
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disease (BBD), smoking, night work, body-mass index (BMI),
height, physical activity, alcohol intake). Effect modification of
HRT by menopausal age or by BBD was tested. Finally, for each of
the prognostic factors, the RR estimates for the favourable and
nonfavourable breast cancer outcomes in current HRT users were
analysed in a competing risks framework using the Wald test. The
likelihood ratio test for two competing risks as described in
Rosthj et al was additionally performed, confirming Wald test
results (Andersen et al, 2002). The analysis was performed in Stata
version 7.0.
RESULTS
In this population of 10874 natural postmenopausal women, a
total of 2726 women (25.1%) were current users of HRT, 1582
women were past users (14.5%) and 6566 women (60.4%) were
never users of HRT at baseline in 1993. Information on the type
and regimen of HRT was available for current users.
A total of 244 women developed invasive breast cancer during
the observation period from baseline in 1993 until 31 December
1999. Histological information was complete for 230 women: 172
invasive ductal carcinomas (74.8%), 36 lobular (15.6%) and 22
‘other histologies’ such as mucinuous, medullary, tubullary and
others (9.6%).
The analysis of breast cancer with different prognostic
characteristics was restricted to women diagnosed with invasive
ductal carcinomas (n¼172). Receptor-positive breast cancer was
seen in 79.8%, low histological malignancy grade was found in
37.3%, negative lymph node status in 56.4%, small tumour size in
58.1%, low stage in 40.1% and good prognostic group according to
NPI in 39.5% (Table 1).
Overall, the risk of breast cancer of all types (n¼244) was
increased for current users of HRT, multivariate RR 2.42 (1.81–
3.26) compared to never users of HRT. The risk of being diagnosed
with invasive ductal carcinomas (n¼172) was increased as well,
multivariate RR 2.49 (1.76–3.51) compared to never users of HRT
(Table 2).
The risk of being diagnosed with a hormone receptor-positive
breast cancer following current use of HRT was significantly
increased with an RR of 3.29 (2.27–4.77) compared to the never/
past use. The risk of being diagnosed with the prognostic less
favourable hormone receptor-negative breast cancer was not
increased with the use of HRT; RR 0.99 (0.42–2.36). The difference
between these two risk estimates among users of HRT was highly
statistically significant (P¼0.013) (Table 3a).
The risk of being diagnosed with a breast cancer of low
histological malignancy grade was increased following the current
use of HRT compared to the never/past use, with an RR of 4.13
(2.43–7.01). This was nearly twice the risk of developing a breast
cancer with a high malignancy grade, RR 2.17 (1.42–3.30), but in
the model of competing risks this difference was not statistically
significant (P¼0.063).
Both the risk of being diagnosed with a lymph node-negative
breast cancer and a lymph node-positive breast cancer was
increased 2.5-fold in current users of HRT compared with never/
past use. The risk of being diagnosed with a small tumour was
equal to the risk of being diagnosed with a larger tumour of more
than 2cm. The RR estimates were equally increased for low- and
high-stage breast cancer among users of HRT and the RR estimates
of developing a good prognostic breast cancer or moderate/poor
prognostic breast cancer according to NPI were equally increased
as much as 2.5-fold (Table 3b and c).
The different HRT types and regimens all increased the RR of
the various breast cancer types. The use of oestrogen only therapy
tended to produce lower risk estimates in general, with no
significant difference between the favourable and non-favourable
breast cancer types, except for receptor status, where the highest
estimate was seen for receptor-positive breast cancer. The risk
estimates following the use of the continuous combined oestro-
gen–progestin regimens were generally higher than following the
cyclical combined regimens, but with overlap in confidence
intervals. The RR estimates with the use of progesterone-like
progestins were higher than with the testosterone-like progestins
when used cyclically, but numbers were small and confidence
intervals overlap, indicating no difference. Tibolone was associated
with the highest risk estimates, especially for the favourable breast
cancer types, such as negative lymph node status, low stage at
diagnosis and good prognostic group according to NPI. These risk
estimates, however, were based on a small number of cases,
allowing no further statistical comparison (Table 3).
DISCUSSION
In the present study, we found that the current use of HRT
increased the RR of being diagnosed with both favourable as well
as nonfavourable breast cancer types, except for hormone receptor
status, where we found significantly higher RR of hormone
receptor-positive breast cancer compared to hormone receptor-
negative breast cancer among current users of HRT. We found a
higher risk of being diagnosed with histological low malignancy
grade as compared to high malignancy grade in current users of
HRT, but this difference was not statistically significant.
Histological malignancy grade and hormone receptor status
represent biological variables, whereas the other prognostic factors
represent time-dependent variables, such as tumour size, lymph
node status and TNM stage. As 90% of breast tumours with low
malignancy grade (grade 1) are hormone receptor positive, the two
prognostic factors somehow resemble each other. A total of 48% of
the current HRT users had tumours that were both hormone
receptor positive and had low malignancy grade, as opposed to
27% among never users of HRT. Current HRT users diagnosed
with tumours of both high histological malignancy grade and
negative receptor status comprised 8%, while the corresponding
figure for never users was 25%. These rough comparisons indicate
Table 1 Descriptive statistics of prognostic factors in women with
invasive ductal carcinomas (n¼172)
Variable Categories All frequency
Receptor status Receptor positive 126 (79.8%)
Receptor negative 32 (20.2%)
Missing
a 14
Malignancy grade Grade 1 60 (37.3%)
Grade 2–3 101 (62.7%)
Missing 11
Lymph node (LN) status Node negative 93 (56.4%)
Node positive 72 (43.6%)
Missing
a 7
Tumour size 2cm or less 97 (58.1%)
More than 2cm 70 (41.9%)
Missing
a 5
Stage (TNM) Stage 1 65 (40.1%)
Stage 2–4 97 (59.9%)
Missing
a 10
Nottingham Prognostic Index (NPI) Good prognosis 60 (39.5%)
Moderate prognosis 77 (50.7%)
Poor prognosis 15 (9.9%)
Missing
a 20
aMissing values are excluded from the analysis.
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is to be explained by receptor status. However, our data do not
allow for further statistical comparisons or stratified analyses as
numbers are too small and thus additional follow-up time is
required.
For the other prognostic factors being time-dependent and
reflecting the stage and development of the disease, such as lymph
node status and tumour size, the risk estimates for the favourable
and non-favourable outcomes were equally increased among
current users of HRT and past/never users. NPI including both
the biological and time-dependent variables showed equally
increased risk estimates throughout prognostic groups (Figure 1).
Our study does not support the notion that breast cancer in
users of HRT is of larger size or diagnosed at a more advanced
stage, nor does our study indicate earlier diagnosis with smaller
tumours and less advanced stage of disease as supposed by the
possible influence of increased surveillance among users of HRT.
Most previous studies have compared the distribution of
prognostic factors in breast cancer cases only among users of
HRT and non-users, respectively. If, in our study, we merely had
focused on the favourable prognostic factors in breast cancer
cases, we would have found a RR of 1.46 (0.99–2.17) for
developing a hormone receptor-positive breast cancer among
users of HRT. These estimates do not reflect the overall increased
incidence of breast cancer with the use of HRT, nor do they reflect
the risk of developing the unfavourable type of breast cancer, and
thus might be misleading. Hence, it is important to base the
analysis on the entire study population, analysing both the
favourable and nonfavourable types of breast cancer according
to HRT.
In the present study, we have furthermore tested whether there
was a difference in being diagnosed with a more favourable cancer
compared to a nonfavourable cancer in current users of HRT, by a
model of competing risks analyses. Similar to our analytic
approach, a recent study has analysed the risk of being diagnosed
with various types of breast cancer in women attending mammo-
graphic screening. The risk of being diagnosed with both
favourable and nonfavourable types of breast cancer was increased
for users of the combined oestrogen–progestin regimens. Even if
no analysis of competing risks was performed, the confidence
intervals outline a higher risk of developing an oestrogen receptor-
positive rather than a receptor-negative breast cancer in users of
HRT for 5 years or more. Furthermore, users of HRT had smaller
tumours at the time of diagnosis, which is counterbalanced by a
higher rate of false-negative examination results (Kerlikowske et al,
2003).
It has previously been shown that in this study population there
is an increased risk of breast cancer following the use of HRT and
that this risk is more pronounced for the combined oestrogen–
progestin HRT regimens, especially for the continuous combined
HRT regimens (Stahlberg et al, 2004). The estimates in the present
analysis seem to confirm these findings; however, numbers are
smaller because of the subdivision into various breast cancer types
of different prognostic characteristics. The risk of breast cancer
following the use of tibolone was significantly increased for all
types of breast cancers, most so for some favourable types, but the
estimates are based on small numbers and confidence intervals are
wide. This finding is partly unexpected, as early reports have
suggested a beneficial effect on breast tissue with the use of
tibolone and the mammographic density was unaffected (Chetrite
et al, 1999; Lundstrom et al, 2002). Tibolone might therefore have
been preferred for women with a family history of breast cancer, as
it has been considered a safer HRT regimen regarding the risk of
breast cancer. It has, however, been proposed in an in vitro study
that tibolone does have tumour cell-growth-promoting effects and
therefore might be unsuited for women at high risk of breast
cancer (Lippert et al, 2002). As our data on family history of breast
cancer are limited, we have not been able to control for familiar
predisposition in our analyses.
Few other studies have analysed breast cancer prognostic
characteristics according to different HRT types and regimen
(Magnusson et al, 1996; Ross et al, 2000; Schairer et al, 2000;
Daling et al, 2003). A Swedish study found that combined
oestrogen and progestin use was associated with lower risks of
being diagnosed with larger tumours above 2cm odds ratio (OR)
0.3 (0.1–0.7) and with positive axillary lymph nodes OR 0.7 (0.4–
1.1) compared to never users. A study from USA found that
oestrogen-only therapy was associated primarily with CIS lesions,
while the combined oestrogen and progestin treatment was
associated with an increased risk of both in situ lesions as well
as low- and high-stage invasive breast cancer (Ross et al, 2000).
Recent studies have found that oestrogen-only users had decreased
odds of being diagnosed with distant disease and that tumours in
women having used the combined oestrogen–progestin HRT
regimens were more often both oestrogen- and progesterone-
receptor positive (Daling et al, 2003; Li et al, 2003). There is no
agreement as to whether the estimates are highest for the
continuous or the cyclically combined regimens. The recent study
by Kerlikowske et al used proxy-variables for HRT type, as it was
assumed that women with an intact uterus had used combined
oestrogen–progestin regimens and women without a uterus had
used oestrogen-only therapy regimens. This might, however,
introduce bias when analysing the effect of different HRT
regimens.
Observational studies have certain limitations and strengths. As
this is a prospective study, there is no recall bias active with
Table 2 The risk of breast cancer with all histologies and invasive ductal carcinoma following the use of HRT
Use of HRT No of HRT users No of cases Breast cancer all types No of cases Breast cancer invasive ductal carcinoma
N¼10874 N (%) N¼244 RR (95% CI)
a N¼172 RR (95% CI)
a
Never 6566 (60.4) 110 1.00 78 1.00
Past 1582 (14.5) 31 1.16 (0.76–1.77) 16 0.85 (0.49–1.50)
Current 2726 (25.1) 103 2.42 (1.81–3.26) 78 2.49 (1.76–3.51)
Never HRT 6566 (60.4) 110 1.00 78 1.00
Past HRT 1582 (14.5) 31 1.16 (0.76–1.77) 16 0.85 (0.49–1.50)
Oestrogen 543 (5.0) 16 1.95 (1.15–3.32) 12 2.03 (1.10–3.75)
E+ prog-P cyclical 433 (4.0) 20 3.02 (1.80–5.05) 15 3.10 (1.69–5.67)
E+ test-P cyclical 1054 (9.7) 32 1.94 (1.26–3.00) 26 2.15 (1.31–3.54)
E+ test-P continuous 431 (3.1) 23 4.16 (2.56–6.75) 17 4.10 (2.29–7.30)
Current Tibolone 79 (0.7) 5 4.27 (1.74–10.51) 4 4.89 (1.78–13.42)
Current other HRT 276 (2.5) 7 1.53 (0.67–3.50) 4 1.10 (0.34–3.45)
E¼oestrogen, P¼progestin, prog-P¼progesterone-like progestin, test-P¼testosterone-like progestin.
aAdjusted for benign breast disease (0, yes; 1, no) and menopausal age
(0o55 years; 1.55+ years).
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lTable 3 (a–c) The risk of invasive ductal carcinoma, with different prognostic characteristics following the use of HRT
(a)
No of cases
Receptor status
positive No of cases
Receptor status
negative No of cases
Low malignancy
grade (grade 1) No. of cases
High malignancy
grade (grade 2+3)
HRT use N¼126/10874 RR (95% CI)
a N¼32/10874 RR (95% CI)
b N¼60/10874 RR (95% CI)
c N¼101/10874 RR (95% CI)
c
Never/past 63 1.00 25 1.00 26 1.00 63 1.00
Current 63 3.29 (2.27–4.77) 7 0.99 (0.42–2.36) 34 4.13 (2.43–7.01) 38 2.17 (1.42–3.30)
Current users pos vs neg receptor.status: P¼0.013 Current users low vs high malignancy grade: P¼0.063
Never 54 1.00 19 1.00 22 1.00 52 1.00
Past 9 0.65 (0.32–1.31) 6 1.30 (0.48–3.55) 4 0.70 (0.24–2.03) 11 0.82 (0.43–1.58)
Current oestrogen 11 2.52 (1.31–4.84) 1 0.70 (0.09–5.22) 2 1.07 (0.25–4.56) 10 2.49 (1.26–4.91)
E+ prog-P Cyclical 15 4.78 (2.60–8.79) 0 na 10 7.62 (3.50–16.57) 4 1.50 (0.53–4.22)
E+ test-P Cyclical 19 2.63 (1.52–4.55) 4 1.62 (0.53–4.95) 9 2.85 (1.28–6.35) 15 2.27 (1.25–4.13)
E+ test-P Continuous 12 4.28 (2.22–8.24) 2 2.27 (0.52–9.90) 9 7.87 (3.59–17.28) 6 2.51 (1.07–5.87)
Current Tibolone 2 3.22 (0.78–13.25) 0 na 1 3.78 (0.51–28.10) 2 3.45 (0.84–14.21)
Current other HRT 4 1.86 (0.67–5.15) 0 na 3 3.34 (0.99–11.23) 1 0.51 (0.07–3.67)
(b)
No. of cases
Lymph node
status negative No. of cases
Lymph node
status positive No. of cases
Small tumour size
(p2cm) No. of cases
Large tumour size
(42cm)
HRT use N¼93/10874 RR (95% CI)
d N¼72/10874 RR (95% CI)
e N¼97/10874 RR (95% CI)
b N¼70/10874 RR (95% CI)
c
Never/past 48 1.00 41 1.00 52 1.00 40 1.00
Current 45 2.58 (1.67–4.00) 31 2.52 (1.32–4.83) 45 2.57 (1.67–3.97) 30 2.74 (1.67–4.50)
Current users neg vs pos lymph node status: P¼0.95 Current users small vs large tumour size: P¼0.86
Never 37 1.00 37 1.00 44 1.00 32 1.00
Past 11 1.11 (0.54–2.22) 4 0.26 (0.04–1.99) 8 0.83 (0.39–1.77) 8 0.95 (0.44–2.06)
Current oestrogen 6 1.86 (0.78–4.42) 5 1.89 (0.55–6.47) 5 1.47 (0.58–3.74) 6 2.41 (1.00–5.78)
E+ prog-P cyclical 8 3.03 (1.33–6.92) 7 3.11 (1.13–8.55) 8 2.77 (1.22–6.27) 7 4.40 (1.88–10.29)
E+ test-P cyclical 16 2.48 (1.31–4.68) 9 1.54 (0.60–3.98) 17 2.32 (1.23–4.36) 8 2.02 (0.90–4.51)
E+ test-P continuous 9 4.02 (1.86–8.70) 8 3.69 (1.24–10.98) 7 3.42 (1.53–7.68) 9 6.24 (2.94–13.22)
Current Tibolone 3 6.50 (1.99–21.18) 1 4.13 (0.55–31.17) 4 8.50 (3.03–23.82) 0 Na
Current other HRT 3 1.31 (0.31–5.45) 1 1.26 (0.17–9.52) 4 1.91 (0.59–6.21) 0 Na
(c)
No. of cases
Low stage
(stage 1) No. of cases
High stage
(stage 2–4) No. of cases
NPI good
prognosis No. of cases
NPI moderate/
poor prognosis
HRT use N¼65/10874 RR (95% CI)
d N¼97/10874 RR (95% CI)
c N¼60/10874 RR (95% CI)
b N¼92/10874 RR (95% CI)
c
Never/Past 33 1.00 55 1.00 30 1.00 54 1.00
Current 32 2.49 (1.49–4.18) 42 2.71 (1.77–4.13) 30 2.61 (1.52–4.47) 38 2.48 (1.60–3.84)
Current users low stage vs high stage: P¼0.81 Current users good prognosis vs mod./poor: P¼0.89
Never 26 1.00 47 1.00 24 1.00 46 1.00
Past 7 1.08 (0.47–2.52) 8 0.65 (0.31–1.38) 6 1.11 (0.45–2.74) 8 0.67 (0.31–1.41)
Current oestrogen 3 1.27 (0.38–4.22) 7 1.88 (0.85–4.18) 1 0.50 (0.07–3.70) 9 2.45 (1.20–5.03)
E+ prog-P cyclical 6 2.86 (1.077.57) 9 3.68 (1.76–7.71) 7 4.56 (1.93–10.78) 7 2.88 (1.27–6.52)
E+ test-P cyclical 12 2.54 (1.23–5.26) 13 2.17 (1.14–4.11) 12 2.47 (1.13–5.41) 11 1.83 (0.92–3.62)
E+ test-P continuous 5 3.36 (1.28–8.80) 11 5.11 (2.62–9.94) 5 3.90 (1.48–10.28) 9 4.29 (2.08–8.84)
Current Tibolone 3 8.61 (2.59–28.61) 1 1.93 (0.27–14.04) 2 7.03 (1.65–29.85) 1 1.97 (0.27–14.32)
Current other HRT 3 1.76 (0.42–7.45) 1 0.56 (0.08–4.10) 3 2.13 (0.50–9.05) 1 0.57 (0.08–4.14)
E¼oestrogen, P¼progestin, prog-P¼ progesterone-like progestin, test-P¼testosterone-like progestin. NPI¼ Nottingham Prognostic Index.
aAdjusted for age, benign breast disease (0, yes; 1, no).
bAdjusted for age, age at
menopause.
cAge adjusted.
dAdjusted for age, age at menopause (0o55 years; 1, 55+years) and use of oral contraceptives (0, no; 1, yes).
eAdjusted for age and night work (0, no; 1, yes).
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lrespect to exposure information on HRT use. This study comprises
a nationwide cohort of Danish nurses and bias by education/social
class is therefore not likely to affect the results. The information on
HRT types and regimens was available only for current users at
baseline, and as in many other prospective cohorts we have no
information on updated exposure. Therefore, misclassification
might occur over time. However, it has previously been shown that
there was a high degree of adherence to therapy regimens among
Danish women using HRT, especially with the use of the
continuous combined regimens over time (Eiken and Kolthoff,
2002). Our data on familiar predisposition are limited and thus in
this study we could not control for this potential confounding
factor. A strong familiar and genetic predisposition would often
result in early premenopausal onset of breast cancer, and breast
cancers developing in younger women have been associated with
poor prognostic characteristics such as high histological malig-
nancy grade (Fisher et al, 1997; Kollias et al, 1997). However, this
cohort comprises of postmenopausal women only and women with
previous breast cancer have been excluded from analysis.
Furthermore, previous studies have not found any effect modifica-
tion by familiar predisposition on the use of HRT (Ursin et al,
2002). Surveillance or detection bias is a major source of bias when
analysing the risk of developing breast cancer with different
prognostic characteristics in women using HRT. We have no
information on the mode of detection in our study. In Denmark,
only two out of 15 counties had mammographic screening
established during the time of observation. The radiographic
detection of breast cancers in women using HRT might be more
difficult because of more dense mammograms, resulting in a
higher false-negative rate in mammographic screening rounds
(Chlebowski et al, 2003; Kerlikowske et al, 2003). On the other
hand, both the physician prescribing HRT and the woman herself
will probably be more aware of the risk of cancer development.
This may result in higher rates of both referrals from physicians
and HRT users for mammographic and ultrasound examination,
even in a screening population. Nurses may have easier access to
radiographic examination as self-referrals. A minor detection bias
is therefore a possibility. However, we compared the stage
distribution in our study with the national results from the DBCG
registry, where low-stage breast cancer during the period of follow-
up was defined as negative lymph node status and tumour size less
than 5cm. The national results from the treatment protocol of 1989
showed that 57% of all breast cancers were low-stage tumours,
which compares to the 55.6% in the present study. The stage
distribution is thus the same, indicating that breast cancer
diagnosed in Danish nurses resembles the whole female popula-
tion. The higher risk of developing breast cancer with a positive
receptor status and to some extent low histological malignancy
grade is therefore considered likely to be associated with the prior
treatment with HRT.
CONCLUSION
In conclusion, the current use of HRT increases the risk of being
diagnosed with both favourable and nonfavourable breast cancers
two- to four-fold. This study shows that, in current users of HRT at
baseline, the RR of developing breast cancer with positive
hormone receptor status is increased, while the risk of developing
a hormone receptor-negative tumour is neutral as compared to the
never/past use. This difference is statistically significant. For the
other prognostic factors, we find no significant difference in risk
estimates for the favourable and nonfavourable prognostic
characteristics with the current use of HRT. Concerning different
HRT regimens, the risk of breast cancer is increased following the
use of any type of HRT, but the highest estimates are seen with the
use of the continuous combined oestrogen and progestin HRT
regimen.
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